Filters

Latest News

2020-03-19 09:51:38

Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis

19 March 2020, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, ...

Read More

2020-03-16 10:30:47

Pharma industry and patient groups collaborate on a NEW guidance note on best practices for interaction

Geneva, March 17, 2020 – The International Association of Pharmaceutical Manufacturers and Associations (IFPMA) and ...

Read More

2019-10-25 05:13:16

Global Health Progress launched to drive cross-sectoral collaborations in support of the Sustainable Development Goals (SDGs)

Global Health Progress is a new knowledge hub highlighting over 200 collaborations between the innovative ...

Read More

2019-01-10 07:49:44

R&D biopharmaceutical industry embraces NEW Code of Practice to boost business integrity worldwide

The new Code of Practice in place from 1 January 2019, imposes a complete ban ...

Read More

2018-12-10 13:14:17

Unjela Kaleem joins global pharma association as Director of Communications

Geneva, 10 December 2018 – IFPMA, the global research-based biopharmaceutical industry association, is pleased to ...

Read More

2018-12-05 12:00:49

R&D biopharmaceutical industry revamp ethical code to apply as base line of industry behavior worldwide

New R&D biopharmaceutical industry Code of Practice comes into effect on 1 January 2019. Changes ...

Read More

2018-12-04 17:17:22

David A. Ricks Elected New President of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company, takes over as ...

Read More

Latest Statement

2020-04-03 08:38:11

IFPMA Backgrounder - COVID-19

Read More

2020-03-19 09:49:06

Global Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis

David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...

Read More

2020-02-12 18:32:08

IFPMA and WHO Global Research and Innovation Forum

David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...

Read More

2020-02-10 07:39:58

IFPMA Members' support in countering the novel coronavirus (2019-nCoV)

David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...

Read More

2020-02-07 16:43:11

WHO EB 146 Agenda Item 20: Data and innovation: draft global strategy on digital health

David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...

Read More

2020-02-07 16:01:28

WHO EB 146 Agenda Items 15.3: Influenza preparedness and 15.4: The public health implications of implementation of the Nagoya Protocol

David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...

Read More

2020-02-07 15:04:08

WHO EB 146 Agenda Item 13: Neglected tropical diseases

David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...

Read More

mailto:s.kaenzig@ifpma.org +41 22 338 32 49
direct line
Twitter skaenzig

Sadia Kaenzig - Communications Manager

Sadia manages communications on issues including regulatory, intellectual property protection, trade and the economic footprint of the research-based pharmaceutical industry, research and development ecosystem and innovation, vaccines including influenza vaccines, and biotherapeutics.

mailto:m.depol@ifpma.org +41 22 338 32 20
direct line
Twitter @MorganePol

Morgane De Pol - Communications and Public Affairs

Morgane manages communications on issues including the research-based pharmaceutical industry’s commitment to achieving sustainable and inclusive development, advancing Universal Health Coverage, designing transformational partnerships to build healthier societies, boosting innovation for neglected tropical diseases, expanding access to high quality treatments for infectious and chronic diseases, fighting counterfeit medicines, and promoting resilient and efficient health systems.

A shared commitment to global health

Our Brouchure

2015 Edition

A shared commitment to global health

At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere.


Our Logo

Full colour EPS format

Our Logo

Full colour PNG format


FULL Name LOGO

Full colour EPS format


FULL Name LOGO

Full colour PNG format

Hot Topic

Pharmacovigilance: Do your bit, play your part!

Pharmacovigilance is one of the key steps to ensuring the safety of all our medicines, including biotherapeutics and vaccines. It encourages an ongoing cycle of communication between patients, health professionals, regulatory authorities, and our biopharma industry which is

Read More

Interview

IFPMA 2015 interview series 'Biodiversity, human health, and pharma'

A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What's key is to

Read More

Our Blog

Latest Tweets

"What can the #NCD community learn from the approaches deployed for infectious disease response?" asks James Pfizer… https://t.co/PP6Zd6895s
2
Older people, and people with preexisting conditions appear to be more susceptible to becoming severely ill with… https://t.co/tfEO7ZNQ63
RT @NCDAccess: Words of wisdom from @WHO for people living with NCDs in the midst of a global health crisis. #COVID19 https://t.co/WD9PSjTr
1
#HealthPartnerships and collaborations are essential to #BeatNCDs. The 4 Healthy Habits project, in collaboration w… https://t.co/nl98A8349u
1
In every country, #doctors and #healthcareworkers are at the frontline of a gigantic struggle to stop the spread of… https://t.co/ako0SreDMZ
1 3